Business Context and Reporting Period
This Form 8-K Current Report was filed by Nephros, Inc. on April 10, 2018, regarding a material definitive agreement entered into on the same date. The company is incorporated in Delaware and maintains its principal executive offices in South Orange, New Jersey.
Key Financial Metrics
The filing details a private placement of equity rather than operational financial results. Key transaction metrics include:
- Shares Issued: 6,540,669 shares of common stock.
- Purchase Price: $0.45 per share.
- Gross Proceeds: Approximately $2,943,301 (before transaction-related expenses).
- Insider Participation: CEO Daron Evans and his two minor children purchased 79,000 shares; CFO Andrew Astor purchased 80,000 shares.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the transaction proceeds.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of capital resulting from the closing of the Stock Purchase Agreement on April 10, 2018. This represents a significant capital raise event compared to the prior period.
Guidance, Outlook, and Covenants
The filing outlines specific covenants and future obligations rather than operational guidance:
- Lock-Up Period: Purchasers are restricted from selling shares for six months following the closing. The Company is also restricted from selling or announcing the sale of common stock or equivalents during this period without lead investor consent.
- Registration Rights: The Company must use commercially reasonable efforts to file a registration statement for the resale of shares by July 9, 2018 (90 days post-closing) and maintain its effectiveness until all shares can be sold under Rule 144 without restrictions.
The filing text does not provide clear values for future revenue guidance, management commentary on operational outlook, or specific risk factors beyond standard agreement terms.
Investor Verification Checklist
- Verify the final net proceeds after deducting transaction-related expenses.
- Confirm the total number of shares outstanding post-transaction to assess dilution impact.
- Review the full Stock Purchase Agreement (Exhibit 10.1) for specific representations and warranties.
- Monitor the status of the registration statement filing by the July 9, 2018 deadline.
- Check subsequent filings for the Company's use of proceeds and updated liquidity position.